# Alvotech Swiss AG clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Alvotech Swiss AG as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alvotech Swiss AG: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/alvotech-swiss-ag

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 23, 2026 | NCT07489131 | Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema | Alvotech Swiss AG | Phase 3 | Recruiting | Diabetic Macular Edema | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489131) |
| March 16, 2026 | NCT07475572 | Pharmacokinetic Similarity Study to Compare AVT32-DRL\_PB With Keytruda® in Participants With Fully Resected Melanoma | Alvotech Swiss AG | Phase 1 | Recruiting | Melanoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475572) |
| December 13, 2024 | NCT06732804 | Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio | Alvotech Swiss AG | Phase 1 | Completed | Healthy Male and Female Subjects | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732804) |
| August 26, 2024 | NCT06570772 | Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio | Alvotech Swiss AG | Phase 3 | Terminated | Ulcerative Colitis | 301 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06570772) |
| May 6, 2024 | NCT06400719 | Pilot Study of AVT16 in Healthy Adult Subjects | Alvotech Swiss AG | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06400719) |
| August 14, 2023 | NCT05986786 | Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease | Alvotech Swiss AG | Phase 3 | Completed | Chorioretinal Vascular Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05986786) |
| May 26, 2023 | NCT05876949 | AVT03 With Xgeva in Healthy Male Subjects | Alvotech Swiss AG | Phase 1 | Completed | This is a Phase I Study Conducted in Healthy Volunteers | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05876949) |
| May 3, 2023 | NCT05842213 | Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX | Alvotech Swiss AG | Phase 3 | Completed | Rheumatoid Arthritis | 502 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05842213) |
| November 30, 2022 | NCT05632211 | A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants | Alvotech Swiss AG | Phase 1 | Completed | Healthy Adult Subjects | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05632211) |
| May 27, 2022 | NCT05395091 | Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND | Alvotech Swiss AG | Phase 3 | Completed | Osteoporosis, Postmenopausal | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05395091) |
| December 13, 2021 | NCT05155293 | Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) | Alvotech Swiss AG | Phase 3 | Completed | Neovascular (Wet) AMD | 413 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05155293) |
| November 19, 2021 | NCT05126784 | AVT03 With Prolia in Healthy Male Subjects | Alvotech Swiss AG | Phase 1 | Completed | Healthy Male Subjects | 209 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05126784) |
| June 18, 2021 | NCT04930042 | Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis | Alvotech Swiss AG | Phase 3 | Completed | Psoriasis | 581 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04930042) |
| February 9, 2021 | NCT04744363 | Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) | Alvotech Swiss AG | Phase 1 | Completed | Psoriasis | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04744363) |
| July 1, 2020 | NCT04453137 | Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis | Alvotech Swiss AG | Phase 3 | Completed | Plaque Psoriasis | 567 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04453137) |
| January 13, 2020 | NCT04224194 | Auto-injector Real Life Handling in Patients | Alvotech Swiss AG | Phase 3 | Completed | RA | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04224194) |
| June 12, 2019 | NCT03983876 | PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) | Alvotech Swiss AG | Phase 1 | Completed | Phase 1 | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03983876) |
| February 21, 2019 | NCT03849404 | Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis | Alvotech Swiss AG | Phase 3 | Completed | Plaque Psoriasis | 413 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849404) |
| February 21, 2019 | NCT03849313 | Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) | Alvotech Swiss AG | Phase 1 | Completed | Healthy Volunteers | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849313) |
| July 9, 2018 | NCT03579823 | Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers | Alvotech Swiss AG | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03579823) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Psoriasis | 2 |
| Arthritis, Rheumatoid | 1 |
| Melanoma | 1 |
| Osteoporosis, Postmenopausal | 1 |
| Macular Degeneration | 1 |
| Retinal Degeneration | 1 |
| Colitis, Ulcerative | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
- [Window suppliers in the United States](https://specstream.ai/data/businesses/window-suppliers/united-states)
- [Neurology practices in the United States](https://specstream.ai/data/businesses/neurology-practices/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
